Prospective, Post Marketing Surveillance Study On Erbitux® (Cetuximab) in Patients With Locally Advanced or Recurrent and/or Metastatic Squamous Cell Cancer of the Head and Neck in Korea

Clinical trial NCT01075828 · COMPLETED

Trial details

NCT number: NCT01075828
Sponsor: Merck KGaA, Darmstadt, Germany
Status: COMPLETED
Study type: OBSERVATIONAL

Head and Neck Cancer

Start date: 2009-03-01
Primary completion: 2014-07-01
Enrollment: 221

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.